Clinical Report: Analysis of T Cell-Mediated Immune Responses in Gastric Cancer

Overview

This bibliometric study analyzes T cell-mediated immune responses in gastric cancer (GC) over two decades, revealing an increase in publications and collaborative networks. Key research themes include immune infiltration, tumor microenvironment, and the impact of emerging technologies on immunotherapy.

Background

Gastric cancer is a leading cause of cancer-related mortality worldwide, with a high incidence in East Asia. The role of T cell-mediated immunity is crucial for anti-tumor responses and the efficacy of immunotherapy in GC.

Data Highlights

Key Findings

• 2,476 publications on T cell immunity in GC were analyzed.
• Annual publications have increased significantly, particularly after 2017.
• China led in global publication and citation outputs over the 20 years.
• Fudan University was identified as the most productive institution.
• Emerging keywords include immune infiltration and drug resistance.
• Keyword shifts are linked to advancements in single-cell sequencing and immune checkpoint inhibitors.

Clinical Implications

Clinicians should stay informed about evolving research trends.

Conclusion

This bibliometric analysis provides an overview of the field's evolution.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Optimizing immunotherapy in advanced gastric cancer: established and emerging biomarkers for precision patient selection
2. Frontiers in Immunology, 2026 -- Unlocking the Potential: Current Landscape and Future Directions of Immunotherapy in Gastric Cancer
3. Frontiers in Immunology, 2026 -- Metabolic reprogramming networks in the gastric cancer tumor microenvironment: an integrated axis of nutrient competition, metabolic crosstalk, and immunosuppression
4. Journal of Clinical Oncology, 2026 -- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
5. Frontiers in Immunology — Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025)
6. FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)
7. FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma
8. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update | Journal of Clinical Oncology
9. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology - PubMed
10. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649. | Journal of Clinical Oncology
11. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial - PubMed
12. Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study | Journal of Clinical Oncology
13. PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials - PubMed
14. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors | Clinical Cancer Research | American Association for Cancer Research
15. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors | FDA
16. Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy